Trial Search Results

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

This study is being carried out to see if a new treatment being tested, called olaparib, is effective in treating ovarian cancer and preventing it from coming back as quickly as it could otherwise do without any medication. The current medical practice is not to take further medications until the cancer comes back.

Stanford is currently not accepting patients for this trial.

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting